<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624766</url>
  </required_header>
  <id_info>
    <org_study_id>2011-1043</org_study_id>
    <secondary_id>NCI-2018-01842</secondary_id>
    <secondary_id>2011-1043</secondary_id>
    <nct_id>NCT01624766</nct_id>
  </id_info>
  <brief_title>Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers</brief_title>
  <official_title>A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of everolimus when given together&#xD;
      with anakinra or denosumab in treating participants with cancers that have spread to other&#xD;
      places in the body and have come back or aren't responding to treatment. Everolimus may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anakinra is&#xD;
      designated to block a protein that is involved in tumor development, new blood vessels&#xD;
      growing, and the spread of cancer. Monoclonal antibodies, such as denosumab, may interfere&#xD;
      with the ability of tumor cells to grow and spread. Giving everolimus and anakinra or&#xD;
      denosumab may work better in treating participants with advanced cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of&#xD;
      anakinra or denosumab in combination with everolimus in patients with advanced cancers who&#xD;
      progressed on standard therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Preliminary assessment of antitumor efficacy of anakinra or denosumab in combination with&#xD;
      everolimus in patients with advanced cancers.&#xD;
&#xD;
      II. Assessment of the pharmacokinetic (PK) profile of anakinra or denosumab in combination&#xD;
      with everolimus.&#xD;
&#xD;
      III. Preliminary assessment of biomarkers.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of everolimus. Participants are assigned to 1 of 2&#xD;
      arms.&#xD;
&#xD;
      ARM I: Participants receive everolimus orally (PO) daily and anakinra subcutaneously (SC)&#xD;
      daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM II: Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1.&#xD;
      Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2012</start_date>
  <completion_date type="Actual">February 24, 2021</completion_date>
  <primary_completion_date type="Actual">February 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of everolimus</measure>
    <time_frame>At 28 days</time_frame>
    <description>If more than 33% of patients enrolled at any particular dose level develop dose limiting toxicity (DLT), the treatment will continue at the dose level immediately below. If not more than 33% of the patients in the cohort develop DLT, this cohort will be considered the MTD. Only DLTs within course 1 (4 weeks) will be counted with respect to the dose-escalation algorithm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Describing the toxicity profile, descriptive statistics will be provided on the grade and type of toxicity by dose level.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>Metastatic Malignant Neoplasm</condition>
  <condition>Recurrent Malignant Neoplasm</condition>
  <condition>Refractory Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (everolimus, anakinra)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (everolimus, denosumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (everolimus, anakinra)</arm_group_label>
    <other_name>Kinaret</other_name>
    <other_name>Kineret</other_name>
    <other_name>rIL-1ra</other_name>
    <other_name>rIL1RN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (everolimus, denosumab)</arm_group_label>
    <other_name>AMG 162</other_name>
    <other_name>AMG-162</other_name>
    <other_name>Prolia</other_name>
    <other_name>Xgeva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (everolimus, anakinra)</arm_group_label>
    <arm_group_label>Arm II (everolimus, denosumab)</arm_group_label>
    <other_name>42-O-(2-Hydroxy)ethyl Rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Certican</other_name>
    <other_name>RAD 001</other_name>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced or metastatic cancers that are refractory to standard therapy,&#xD;
             relapsed after standard therapy, or who have no standard therapy available that&#xD;
             improves survival by at least three months.&#xD;
&#xD;
          -  Patients must be &gt;= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or&#xD;
             therapeutic radiation, or major surgery. Patients may have received palliative&#xD;
             localized radiation immediately before or during treatment provided that radiation is&#xD;
             not delivered to the only site of disease being treated under this protocol. For&#xD;
             biologic/targeted agents patients must be &gt;= 5 half-lives or &gt;= 3 weeks form the last&#xD;
             dose (whichever comes first).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/mL.&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mL.&#xD;
&#xD;
          -  Creatinine clearance &gt;= 35 ml/min.&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 X upper limit of normal (ULN) (exceptions may apply to benign&#xD;
             non-malignant indirect hyperbilirubinemia such as Gilbert syndrome). Exception for&#xD;
             patients with liver metastasis: total bilirubin =&lt; 3 x ULN.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) and or&#xD;
             aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =&lt; 5&#xD;
             X ULN. Exception for patients with liver metastasis: ALT (SGPT) =&lt; 8 X ULN.&#xD;
&#xD;
          -  Fasting lipid profile: cholesterol =&lt; 350 mg/dL.&#xD;
&#xD;
          -  Fasting lipid profile: triglycerides =&lt; 400 mg/dL.&#xD;
&#xD;
          -  Corrected calcium &gt;= 8.4 mg/dL.&#xD;
&#xD;
          -  Phosphorus &gt;= 2.5 mg/dL for denosumab.&#xD;
&#xD;
          -  Oral examination and appropriate preventive dentistry will be performed prior to the&#xD;
             initiation of denosumab therapy.&#xD;
&#xD;
          -  Negative tuberculosis quantiferon test for anakinra arm.&#xD;
&#xD;
          -  Negative serology for histoplasma, blastomycosis, and Coccidioidomycosis for anakinra&#xD;
             arm.&#xD;
&#xD;
          -  Negative serology for active hepatitis B and C for anakinra arm. Patients with&#xD;
             positive serology for hepatitis B might eligible if they are willing to take&#xD;
             lamivudine preventive therapy.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 30 days after the last dose.&#xD;
&#xD;
          -  Patients must be able to understand and be willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including, but not limited to, uncontrolled&#xD;
             infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support.&#xD;
             Treatment of pre-existing invasive fungal infections must be completed prior to&#xD;
             starting treatment.&#xD;
&#xD;
          -  Patients with an active infection.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  History of hypersensitivity to anakinra.&#xD;
&#xD;
          -  History of hypersensitivity to denosumab.&#xD;
&#xD;
          -  History of hypersensitivity to everolimus.&#xD;
&#xD;
          -  History of hypersensitivity to any component of the formulation.&#xD;
&#xD;
          -  Patients unwilling or unable to sign informed consent document.&#xD;
&#xD;
          -  Patients treated with TNF antagonists.&#xD;
&#xD;
          -  Patients with a history of active systemic fungal infection.&#xD;
&#xD;
          -  Patients with liver disease Child Pugh classification B and C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Janku</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

